CRADD and B-cell non-Hodgkin lymphoma: Our data show that loss of Raidd is dispensable for the development of B-cell lymphomas in the Eμ-Myc mouse model and that Raidd deficiency has no impact on the development, proliferation and cell death of premalignant and transformed cells (Figure 2).